Latest UCB Inc. Stories
ATLANTA, June 9, 2011 /PRNewswire/ -- UCB, Inc. today announced an agreement with the U.S. Department of Justice (DOJ) to resolve a previously disclosed government investigation into the marketing and promotion of KeppraÂ®, an anti-epileptic prescription medicine.
BALTIMORE, May 31, 2011 /PRNewswire/ -- UCB announced findings of the first cost-effectiveness analysis of VimpatÂ® (lacosamide) as add-on therapy for adults with uncontrolled partial-onset seizures.
- The parings of haberdine; also, any kind of fragments.